← Back to Search

Behavioral Intervention

Cognitive Rehabilitation for Multiple Sclerosis

N/A
Waitlist Available
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A define diagnosis of multiple sclerosis (which will include clinically isolate syndrome, radiologically isolated syndrome and neuromyelitis optica spectrum disorder)
Be older than 18 years old
Must not have
Unable or unwilling to travel to the Centre or requires transportation by ambulance
Use of illicit drugs, phencyclidine (PCP), Lysergic acid diethylamide (LSD), stimulants, amphetamines, barbiturates, etc. (Cannabis use is accepted)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 weeks immediate post assessment, and 6 months post assessment
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve the cognitive abilities of people with multiple sclerosis (MS) through a program called Goal Management Training (GMT). The study will have a treatment group that receives the GMT program and a

Who is the study for?
This trial is for individuals with Multiple Sclerosis who experience cognitive challenges, particularly in processing information, learning and memory, or executive function. Participants must be willing to undergo cognitive rehabilitation training.
What is being tested?
The study tests Goal Management Training (GMT) as a form of cognitive rehabilitation for MS patients. It's a randomized controlled trial where the treatment group receives GMT sessions over 5 weeks and their progress is compared to a wait-list control group receiving usual care.
What are the potential side effects?
Since the intervention involves non-invasive cognitive training exercises, no significant physical side effects are expected. However, participants may experience mental fatigue or frustration during the process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a form of multiple sclerosis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot travel to the Centre on my own or need an ambulance for transportation.
Select...
I do not use illicit drugs except for cannabis.
Select...
I have a history of a brain or spinal cord disease that is not multiple sclerosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 weeks immediate post assessment, and 6 months post assessment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks immediate post assessment, and 6 months post assessment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with improved Information processing speed
Secondary study objectives
Number of participants with improved executive function
Number of participants with improved learning and memory
Other study objectives
Number of participants with improved anxiety symptoms
Number of participants with improved depression symptoms
Number of people with improved fatigue symptoms

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: cognitive rehabilitation groupExperimental Treatment1 Intervention
will be treated by GMT for 5 weeks (two hour sessions per week, one day of rest in between).
Group II: wait-list control groupActive Control1 Intervention
will be given a list cognitive compensatory strategies that they can do on their own to improve their memory.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Goal Management Training
2017
N/A
~1150

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,439 Total Patients Enrolled
5 Trials studying Multiple Sclerosis
568 Patients Enrolled for Multiple Sclerosis
~8 spots leftby Dec 2024